SRF is a compounder if three linked transitions work: HFC cash generation through the 2026 baseline, HFO and fluoropolymer capacity converting from FY28, and Specialty Chemicals revenue recovery converting into margins. Q2 FY27 shows the first two progressing while the third remains uneven.
The business economics rest on two moats. In Fluorochemicals, SRF is backward integrated into HF and holds an HFC position capped by the Kigali baseline. That makes current HFC plants a finite cash engine: SRF cannot add capacity, so it plans to run existing plants flat out through December 2026 to maximise the baseline. In Q2 FY27, Fluorochemicals was strong on higher HFC volumes, improved realizations and newer markets including the Middle East; management said the push into newer markets was not at the cost of profitability and in some cases generated better prices. The US market was softer and buying a different product mix. Refrigerant demand and pricing are expected broadly stable barring normal seasonality. The Hague HFC expansion is progressing. This is not a volume growth business after 2026, but it funds the transition.
In Specialty Chemicals, the moat is customer qualification and molecule registration. Q2 FY27 Chemicals revenue rose 25% to ₹2,079 crore, but Specialty remained challenging. Agrochemical demand recovered in select pockets, and registrations for two AI products progressed in Brazil and other initial markets; management said there is a lag before full demand and intermediates may still be sourced from SRF in the interim. Pharma is the deliberate mix shift: roughly 10% of Specialty Chemicals revenue with a target of at least 20%. In Q2 FY27, two specific pharma customers were progressing; with one, a larger oncological product, management expected meaningful volume and revenue to start ticking through quickly, while the second was earlier stage and no revenue outlook was given. The second Dahej pharma plant was not updated in the Q2 call, so its commissioning remains unverified. Management expects stronger H2 FY27 Specialty revenue on better volumes, but explicitly did not declare victory on margins; raw material and freight costs are elevated, pass-through is better in refrigerant gases than Specialty, and Q2 was called reasonably representative for the gas side.
The next leg is capital-intensive and dated. The Gopalpur HFO project has secured key regulatory approvals and is targeted for commissioning in Q4 FY28; on commissioning, SRF expects to be among the top three to four refrigerant gas manufacturers globally. Initial sales are expected largely in Western markets, using existing distribution and customer relationships. Management expects HFO prices at a significant premium to HFC even after an expected decline when patents expire, and meaningful volumes typically take about 10-12 months after commissioning. In-house HF integration is also intended to address electronic-grade HF for wafer cleaning in semiconductors. HFO revenue is therefore a FY29 event, not a Q4 FY28 step-change.
The Chemours fluoropolymer plants are the other dated fluorochemicals project. SRF is building higher-end fluoropolymer capacity for Chemours, with PTFE excluded. The first plant should be up on the first product in Q4 FY27 and the second in Q1 FY28, with full-scale ramp taking about 10-12 months. Management indicated full-stream revenue from the start of 2028-29 as transcribed; the exact fiscal reading is ambiguous. That is later than the January 2026 calendar-2026 framing recorded in existing research. The contract-manufacturing structure gives SRF a technology-backed revenue stream in semiconductor, automotive, aerospace and chemical-processing supply chains, but the economics remain undisclosed and the ramp is not yet proven.
The new ₹600 crore Jaitapur aluminium foil facility adds a second energy-storage leg. The board approved about 12,000 tpa of capacity for lithium-ion and sodium-ion battery applications plus high-end packaging foil, split into two phases. Phase 1 is about ₹300 crore and targeted within about 23 months; battery qualification realistically takes about two years from readiness. The universal mill can make battery-grade and high-end packaging foil, so SRF can sell aseptic and other high grades while battery qualifications continue. Management put foil prices at about 1.5 times plain packaging foil, with aseptic at a 30-40% markup and battery significantly higher, and expects the existing aluminium foil business to be profitable on an exit basis this year. The ECC PLI scheme is demand support for domestic battery localisation, not a guarantee of SRF offtake.
Performance Films & Foil is the near-term mix support. Q2 FY27 revenue rose 51% to ₹2,122 crore from ₹1,408 crore, with demand robust across geographies and asset utilization strong, though customer procurement moderated after elevated Q1 buying and higher raw material prices reduced inventory-related benefits. Capacitor-grade film has scaled up with key customer approvals and commercial sales ahead of initial timelines; aluminium foil for capacitors is expected to start commercial sales in Q3 FY27, and the hybrid BOPP/BOPPE line is expected to commercialise in Q3 FY27. Management said a second capacitor line already has approval and may be planned sooner than later. Technical Textiles also had a strong Q2, with revenue up 25% to ₹594 crore and belting fabrics strong on exports.
Capital allocation is the central debate. SRF is funding the Odisha HFO project, Chemours fluoropolymer plants, the Dahej pharma plant, the Jaitapur battery-foil facility and film-line upgrades at the same time. The HFC business generates cash through the 2026 baseline, but it is finite. The new projects have long lead times: HFO commissioning in Q4 FY28 and meaningful volumes later; Chemours full stream from 2028-29; Jaitapur Phase 1 in about 23 months and battery qualification about two years. The company has not disclosed return ratios for these projects, so the thesis cannot rely on a calculated return on capital. It relies on the projects reaching utilisation and earning the described premiums to HFC and commodity film. Analyst inference: revenue recovery can arrive before margin recovery; the company has not guided to a specific Chemicals margin.
Q2 FY27 consolidated revenue was ₹4,904 crore, up 35% YoY, operating EBIT was ₹816 crore, up 26%, and PAT was ₹509 crore, up 31%; H1 FY27 revenue was ₹9,937 crore, up 33%, operating EBIT ₹1,932 crore, up 44%, and PAT ₹1,268 crore, up 55%. Management reiterated FY27 Chemicals revenue growth towards the higher end of 15-20%. The earnings path is therefore not a clean operating-leverage story in Q2: revenue grew faster than operating EBIT, and Specialty margin conversion is the swing factor.
Management delivery is mixed. FY27 Chemicals guidance has been reiterated, HFC maximisation is consistent with the quota logic, and Odisha approvals have progressed. But the Chemours timeline moved later, and the supplied bundle contains only the Q2 FY27 transcript, so January 2026 commitments on Q4 FY26 Specialty recovery, the Dahej plant and the FY26 AI launch cannot be verified here. The transcript also renders a fluoropolymer partnership as QEMOS, which is not silently corrected.
Falsifiers are clear. The thesis weakens if H2 FY27 Specialty Chemicals revenue does not accelerate, or accelerates without margin conversion; if HFO commissioning slips beyond Q4 FY28 or HFO pricing falls faster than expected after patents expire; if Chemours slips beyond Q4 FY27/Q1 FY28; if Jaitapur battery qualification takes materially longer than about two years or EV/storage demand disappoints; if films margins fall below the prior 8-12% baseline as raw material costs stay elevated; or if HFC pricing weakens in the 2026 baseline. The thesis strengthens if the high-end 15-20% Chemicals guidance is delivered with Specialty margin improvement, HFO commissioning is on time, Chemours reaches full stream around 2028-29, and the battery-foil project converts into qualified battery sales.
companyname: SRF Limited ticker: SRF sector: Diversified Chemicals / Industrial Intermediates SRF Limited is a diversified chemicals and materials company incorporated in 1970, majority-owned by KAMA Holdings (50.21%) and run by the founding Bharat Ram family. Chairman and Managing Director Ashish Bharat Ram leads a business with five segments: Specialty Chemicals, Fluorochemicals, Performance Films & Foil, Technical Textiles, and two small textile fabric businesses (Laminated and Coated). In F...
Read the full report →capex, margin expansion, new product segment
Management explicitly guides FY27 Chemicals revenue growth towards the higher end of 15-20% and expects stronger H2 FY27 Specialty Chemicals revenue than H1. It targets HFO commissioning in Q4 FY28, first Chemours plant on first product in Q4 FY27 and second in Q1 FY28, aluminium foil capacitor and hybrid BOPP/BOPPE commercialisation in Q3 FY27, and Jaitapur battery-foil Phase 1 completion within about 23 months of board approval.
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for SRF Limited and 4,900+ companies.
5-day free pass. No card required.